A memo from Jack Wood stated that for inventory which could not be reallocated by Cutter US they were to seek a one year extension from NIBS to allow them to relabel and sell over the coming year into markets not yet converted to heat-treated Factor 8 products. Read more about A memo from Jack Wood stated that for inventory which could not be reallocated by Cutter US they were to seek a one year extension from NIBS to allow them to relabel and sell over the coming year into markets not yet converted to heat-treated Factor 8 products.
A letter from Jack Wood at Cutter stated that Cutter felt it was prudent to no longer effect sales of non-heat-treated product for use in the UK following dramatic changes in the UK regarding heat-treated Factor 8 products. Read more about A letter from Jack Wood at Cutter stated that Cutter felt it was prudent to no longer effect sales of non-heat-treated product for use in the UK following dramatic changes in the UK regarding heat-treated Factor 8 products.
A memo from Linda Frith showed the total volume of returned regular material and total sales of Koate, and that for a short period of time Cutter would take a share of the NHS Factor 8 market. Read more about A memo from Linda Frith showed the total volume of returned regular material and total sales of Koate, and that for a short period of time Cutter would take a share of the NHS Factor 8 market.
Horowitz et al discussed their viral inactivation study in this paper which was later put into production by the New York Blood Centre. Read more about Horowitz et al discussed their viral inactivation study in this paper which was later put into production by the New York Blood Centre.
A paper discussed Cutter continuing to carry out studies in the hope of finding ways in which Konyne product may be rendered non-infective. Read more about A paper discussed Cutter continuing to carry out studies in the hope of finding ways in which Konyne product may be rendered non-infective.
An article by Robert J Gerety and Lewellys F Barker described viral inactivation as one of the measures of interest since 1975 undertaken with hopes of increasing safety of haemophiliacs from HBV. Read more about An article by Robert J Gerety and Lewellys F Barker described viral inactivation as one of the measures of interest since 1975 undertaken with hopes of increasing safety of haemophiliacs from HBV.
Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat-treated Factor 8 concentrate. Read more about Gilbert C et al published an article in "The Lancet" describing a case of seroconversion of AIDS in a person with mild haemophilia after administration of high doses of heat-treated Factor 8 concentrate.
The Medical and Scientific Advisory Council of the US National Hemophilia Foundation endorsed the use of heat-treated products. The CDC endorsed the use of heat treatment. It carried out the viral inactivation studies on infectious particles in cooperation with Cutter Laboratories. Read more about The Medical and Scientific Advisory Council of the US National Hemophilia Foundation endorsed the use of heat-treated products. The CDC endorsed the use of heat treatment. It carried out the viral inactivation studies on infectious particles in cooperation with Cutter Laboratories.
The "Morbidity and Mortality Weekly Report" included figures from Cutter which showed that their heat treatment process had inactivated HTLV-3 virus to a degree that the virus was undetectable after 24 hours of heat treatment. Read more about The "Morbidity and Mortality Weekly Report" included figures from Cutter which showed that their heat treatment process had inactivated HTLV-3 virus to a degree that the virus was undetectable after 24 hours of heat treatment.
The "Morbidity and Mortality Weekly Report" stated that the Medical and Scientific Advisory Council of the National Hemophilia Foundation recently issued revised recommendations for haemophilia therapy which included that the use of non-heat-treated factor concentrates should be limited. Read more about The "Morbidity and Mortality Weekly Report" stated that the Medical and Scientific Advisory Council of the National Hemophilia Foundation recently issued revised recommendations for haemophilia therapy which included that the use of non-heat-treated factor concentrates should be limited.